Hormone replacement therapy: Time to move on?

Journal of the British Menopause Society

Volumn 12, Issue 2, 2006, Pages 75-80

  Davey, Dennis A ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Age; Assesment; Guidelines; Hormone replacement theraphy; Risk

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEAR; FEMALE; FRACTURE; FREQUENCY ANALYSIS; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRACTICE GUIDELINE; PRESCRIPTION; PROBABILITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT PLANNING; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

CONFOUNDING FACTORS (EPIDEMIOLOGY); ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 33745072109     PISSN: 13621807     EISSN: 13621807     Source Type: Journal    
DOI: 10.1258/136218006777525767     Document Type: Article

References (31)

1. Grodstein F. Manson J, Coldlitz G. Willett W, Speizer F. Stampfer M. A prospective, observational study of post-menopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41
2. Hulley S, Grady D, Bush T, et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13
3. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women. JAMA 2002;288:321-33
4. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy JAMA 2004;291:1701-12
5. Ettinger B. Grady B. Tostesen A. Pressman A. Maser J. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-32
6. Burgers J, van Everdingen J. Beyond the evidence in clinical guidelines. Lancet 2004;364:392-3
7. Elmore J, Gigerenzer G. Editorial Benign breast disease - the risks of communicating risk. N Engl J Med 2005;353:297-9
8. Elmore J. Gigerenzer G. The editorialists' reply. N Eng J Med 2005;353:1857
9. Council for International Organizations of Medical Sciences (CIOMS). Guidelines for Preparing Care Clinical-Safety Information of Drugs (2nd edn). Geneva: CIOMS, 1998
10. Chlebowski R. Hendrix S. Langer R. et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 2003;289:3243-53
11. Chlebowski R, Wactawski-Wende J. Ritenbaugh C. et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350:991-1004
12. Manson J, Hsia J. Johnson K. et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34
13. Wassetheil-Smoller S. Hendrix S, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA 2003;289:26733-84
14. Cushman M, Kuller I. Prentice R, et al. Estrogen plus progestin risk of venous thrombis. JAMA 2004;292:1573-80
15. Hsia J, Langer RD, Manson JF., et al. Conjugated equine estrogens and coronary heart disease. The Women's Health Initiative. Arch Intern Med 2006;166:357-65
16. Grodstein F, Manson JF, Stampler M. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health 2006;15:35-44
17. Clarkson T, Appi S. Controversies about HRT - lessons from monkey models. Maturitas 2005;16:64-74
18. Mansen JE, Bassuk SS, Harman M, et al. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006;13:139-47
19. Lobo RE. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women. Arch Intern Med 2004;164:482-4
20. Kannel WB, Hjortland MC, McNannara PM, Gordon T. Menopause and risk of cardiovascular disease. The Framingham Study. Ann Intern Med 1976:85:447-52
21. Kalin MF, Zumoff B. Sex Hormones and coronary disease: a review of clinical studies. Steroids 1990;55:330-52
22. Kanis J. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-36
23. Guthrie J, Dennerstein L, Taffe J, Lehert P, Burger H. Hot flushes during the menopause transition: a longitudinal study in Australian women. Menopause 2005;12:460-7
24. Writing Group for the British Menopause Society Council. Managing the menopause. British Menopause Society Council consensus statement on hormone replacement therapy. J Br Menop Soc 2005;11:152-6
25. North American Menopause Society. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of the North American Menopause Society. Menopause 2004;11:589-600
26. Scarabin P, Oger E, Plu-Bureau G, et al. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32
27. Wactawski-Wende J, Kotchen JM, Andrson GL, et al. Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-96
28. Jackson RD, LaCroix AZ, Gass M, et al. Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-83
29. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative randomized controlled dietary modification trial. JAMA 2006;295:629-42
30. Beresford SAA, Johnson KC, Ritenhaugh C. et al. Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative randomized controlled dietary modification trial. JAMA 2006;295:643-54
31. Howard BV, Van Horn L. Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease the Women's Health Initiative randomized controlled dietary modification trial. JAMA 2006; 295:655-66